A Norwegian customization of the Arthritis Cost Consequence Evaluation System (ACCES) pharmacoeconomic model was used to predict the economic and health impact of the introduction of celecoxib in Norway. The model predicts that use of celecoxib can be expected to result in a reduction in gastrointestinal events with concomitant annual net savings of at least Norwegian krone (NOK) 580 per osteoarthritis (OA) patient and NOK 514 per rheumatoid arthritis (RA) patient. In a cost-effectiveness analysis, celecoxib demonstrated economic dominance (i.e. improved health at reduced cost) compared with the currently available alternatives. In sensitivity analyses, the results of this model have been shown to be relatively robust, with celecoxib demonstrating economic dominance or favourable cost-effectiveness ratios in all analyses. Based on these data, it can be concluded that the introduction of celecoxib into the Norwegian non-steroidal anti-inflammatory drug market, and its use as a first-line agent, will provide societal benefits by improving health care at reduced cost in patients with OA and RA.
RA patients that their characteristics were similar to the mean patient characteristics on which the original risk equation was based, i.e. that of the ARAMIS (Arthritis, Rheumatism, and Aging Medical Information System) database. For OA, the mean population characteristics of a large, international clinical trial were used [13] .
As specific prevalence rates for OA and RA are not available from Norway, the prevalence estimates of these diseases were based on a previously published prevalence study in the USA [14] and hospital discharge records from Norway [15] . Since not all patients use or can use NSAIDs, the prevalence rates were combined with an assumption that~80% of this population are on active NSAID treatment. It was estimated that 100 000 OA patients would be treated with NSAIDs, with the model allowing for a maximum 6-month duration of treatment within the scope of the model period of 1 yr, while 40 000 RA patients would be treated with NSAIDs for a 9-month period. Treatment for OA is more intermittent than for RA, and accounts for the difference in duration.
The base rates of symptomatic ulcers and anaemia were calculated as a product of the incidence rate of serious GI events as obtained from the modified Fries risk calculator and the ratio of total symptomatic ulcers to total serious GI events (7.16) , or the ratio of anaemia to total serious GI events (2.64) as obtained from celecoxib-based trials. These ratios, which are based on clinical evidence, are the same as those used for the Swedish model [16] , but different from the ratios suggested in the original model discussion [11] . However, in our sensitivity analysis, the ratios were reduced by 50% to determine the sensitivity of the results using a more conservative estimate.
The weighted cost and relative risk of the Norwegian NSAID basket were calculated based on NSAIDs that had ≥5% of the prescription market share in Norway in 1999. The market share was determined using defined daily dose, and was adjusted according to the average dosages based on data from the MEMO database (Medicines Monitoring Unit) at the University of Dundee in Scotland. This database gives estimates of the relative risks of the drugs at low, medium and high dosages. The average dosages used in the ACCES model are similar to the medium-dosage category. The use of these dosages for the Norwegian analyses was validated both by a comparison with observational data in the US Protocare database, which reports similar dosages, and by confirmation with Norwegian clinical experts. The Norwegian NSAID basket consists of diclofenac, piroxicam, naproxen, ibuprofen and ketoprofen. The NSAID basket was costed based on the above methods in combination with weighted unit costs for each NSAID based on sales figures for 1999 expressed in Norwegian krone (NOK; NOK~8.7 = US$1), i.e. the most sold naproxen formulation has the greatest effect on naproxen cost. Thus, a daily cost of NOK 4.70 (excluding 23% VAT) was calculated for the Norwegian NSAID basket. The daily cost and relative risk of the individual drugs as well as of the total basket are shown in Table 2 .
Costing for celecoxib was based on a dosing regimen of 200 mg QD for OA patients (NOK 7.90). For RA patients, a cost of NOK 10.23 was used based on an assumed dosing regimen distribution of 50% 200 mg QD, 25% 200 mg BID and 25% 100 mg BID. These unit costs (excluding 23% VAT) are based on the prices for Norway approved by Norwegian authorities. Costs for gastroprotective agents were based on the most widely sold PPI (omeprazole, NOK 13.94) or H2-receptor antagonist (H 2 -RA) (ranitidine, NOK 8.39), or on an assumed dose regimen of 0.2 mg BID of misoprostol (NOK 5.84) or 50 mg TID of Arthrotec ® (fixed-dose diclofenac/misoprostol; NOK 9.79).
Expected resource utilization was estimated using questionnaires sent to clinical experts. For determination of resource utilization for serious GI events, a questionnaire was sent to two surgeons, and for resource utilization associated with the treatment of ulcers, anaemia and GI discomfort, respondents included four general practitioners and four rheumatologists. Costs of hospitalization, out-patient procedures and medication were based on 1999 pricing using official Norwegian sources [Forskrifter of takster for offentlige poliklinikker fra 1 april 1999; SINTEF, Norsk institutt for sykehusforskning, Sykehussektoren på 90-talet, rapport 1/98; [12, 17] . For analysis in the ACCES model, we have used a conservative mortality estimate of 10%. These lives lost are converted into life-years, using the average life expectancy for individuals at the average age of the population. Life-years gained are based on the estimated number of GI-associated deaths within the 1-yr period in the population. For the basic analysis, a discount rate of 5% is used in the calculation.
In the model, celecoxib is predominantly evaluated against an NSAID monotherapy alternative consisting of the Norwegian NSAID basket described above, and against base-case scenarios for OA and RA constructed based on the estimated current distribution among the different available treatment options (Table 3) . In these evaluations, the incremental cost-per-event-avoided and cost-per-life-year-gained values are used to establish the incremental cost-effectiveness ratios.
Sensitivity analyses
As with any model that evaluates health economics, uncertainties and assumptions inherent in developing the model can influence outcomes. To determine the robustness of the Norwegian ACCES model, several one-way sensitivity analyses were performed to evaluate the effect of these assumptions on the outcomes. The choice of variables for use in the sensitivity analyses was based on the model components or assumptions that were identified as potentially having the greatest impact on the model outcome.
Since the model is strongly driven by the relative risks for the NSAID treatment, it is important to demonstrate how these may influence the model outcome. The relative risks of NSAID-induced GI events drive the absolute risks of the population, which in turn drive the predicted GI event costs as well as the risks and costs of the post-event switch in therapy. Additionally, the relative risks of the NSAID basket are driven by NSAID dosages, which in turn drive the daily drug cost estimates.
The model assumes a medium dose of NSAID; therefore, for the sensitivity analysis, relative risk was recalculated based on a low NSAID dose. This recalculation reduces the relative risk of the NSAID basket for serious GI events, ulcer and anaemia from 1.27 to 0.90, and from 1.09 to 0.97 for GI discomfort. Moreover, it also reduces the NSAID basket daily drug cost by 30%. As it is unlikely that the RA population will be prescribed lower dosages than those assumed in the model, this sensitivity analysis is run for the OA population only.
The current model uses only a single point-estimate of the composite risk score for serious GI events rather than a risk-score distribution. As the risk scores of the population in the celecoxib clinical trials displayed a non-normal distribution with a median risk score slightly lower than the mean, it was important to perform a sensitivity analysis on this variable. The risk score was increased and decreased by 30% in this analysis.
As discussed above, the ratios for anaemia and symptomatic ulcers were reduced by 50% (from 2.64 to 1.32 for anaemia and from 7.16 to 3.58 for symptomatic ulcers) to provide a more conservative analysis than that provided in the basic Norwegian model.
Two sensitivity analyses were performed based on the duration of therapy: one in which the maximum-allowed length of therapy within the 1-yr model was reduced by 50% and the other based on the assumption that the patients are receiving therapy for 365 days per year (given that they experience therapeutic success without any events). Altering the assumed length of therapy affects the expected initial drug costs and the absolute risk of GI events, which in turn will affect the additional drug costs and event costs.
Once a GI event has been treated and resolved, the model allows for switching the patients to a second-line treatment. Table 4 shows the assumptions for post-event switches in therapy for two scenarios. In the basic model (shown in italics), only treatment options available in the Norwegian market are allowed, i.e. patients in the NSAID arm cannot be switched to celecoxib. Given this restriction, the switch therapy options are consistent with current practice and are motivated by the ability to evaluate a new drug (celecoxib) vs current treatments. In a sensitivity analysis, we allow for switching to celecoxib, which allows for a change in perspective from the current Norwegian situation to a possible future scenario (shown in bold), where celecoxib is on the market. It should be noted that the model populations are based on the prevalence assessment that these patients require NSAID treatment, and thus it is assumed that all patients are to be prescribed a second-line treatment.
A sensitivity analysis was also performed based on an assumed 50% reduction in the costs of adverse events. This allows evaluation of the stability of the results under the assumption that the costs of the resources used for treating adverse events are overestimated in the basic analysis.
Results and discussion
The health economic assessment used in this analysis can be viewed as a population cost-effectiveness model that describes, from a societal perspective, the impact of introducing celecoxib in Norway on direct societal costs and the number of GI events. Separate analyses are presented for OA and RA. Comparisons of celecoxib are made primarily against NSAID monotherapy (which represents the most common treatment alternative and the alternative with the lowest drug price) and the base-case scenarios derived from the current distribution among the available treatment options, as described in Table 3 . Evaluation against both of these alternatives provides a spread of results. Comparison with the NSAID monotherapy arm (i.e. the NSAID basket without use of gastroprotective agents) provides information on the relative costeffectiveness for individual patient treatment strategies (i.e. initiating the patients on celecoxib treatment rather than NSAID treatment). From a national reimbursement perspective, however, a comparison against the base case is more relevant, since it more accurately reflects the Norwegian situation. Table 5 shows the yearly costs per patient for the celecoxib, NSAID monotherapy, base case and rofecoxib treatment arms, while Table 6 presents the expected yearly cost differences per patient for celecoxib vs the alternate treatments.
As shown in these tables, the expected total costs of drugs in the NSAID monotherapy arm are lower than those predicted in the celecoxib arm. This is not surprising given that (i) NSAID monotherapy is the least expensive treatment available and (ii) patients in this treatment arm have a shorter duration of initial therapy, since this arm has the highest incidence rates for GI events. However, as also shown in the tables, use of celecoxib will result in an overall annual cost savings (reduction in total net costs) vs NSAID monotherapy for both OA and RA, primarily due to an expected reduction in GI events and therefore reduction in resource utilization. The calculations suggest that introducing celecoxib and switching patients from NSAID monotherapy to celecoxib would reduce the average yearly per-patient cost for treating GI events by 55% (NOK 756) and 56% (NOK 1233) for OA and RA, respectively, with annual total net cost savings of NOK 580 per OA patient Table 3 ). Base-case scenarios were derived from the current distribution among the available alternative treatment options (see Table 3 ).
and NOK 514 for RA. The corresponding per-patient savings in annual total treatment costs that could be expected by switching to celecoxib from the base case would be NOK 1098 and NOK 1462 for OA and RA, respectively; both drug costs and event costs are reduced with use of celecoxib. Against the base case, some of the expected cost savings with celecoxib are probably due to the reduction in use of more expensive gastroprotective agents such as PPIs.
No differences in event costs are demonstrated vs rofecoxib for OA, since the assumption of the model is that both celecoxib and rofecoxib have identical safety profiles; total cost savings are demonstrated, however, due to differences in drug cost. By switching a random base-case OA patient to celecoxib, rather than rofecoxib, there is an expected 22% saving (NOK 333) in the cost of drug per patient per year.
Substantial cost savings with celecoxib vs other treatment arms (NSAID + PPI; NSAID + H 2 -RA; NSAID + misoprostol; Arthrotec ® ) were also predicted for all cost categories in both OA and RA (data not shown), with the greatest cost savings being demonstrated against NSAID + PPIs, as also shown in the Swedish model [16] .
The introduction of celecoxib is not only a cost or budget impact issue, but its favourable GI safety profile also significantly impacts the individual patient's health as well as the total health effects in the population. The expected annual differences in GI events for celecoxib vs NSAID monotherapy and the base case are shown in Table 7 , based on the assumed population sizes. The data suggest that there are significant health gains in terms of a reduced number of GI events for celecoxib relative to these alternatives. For the other treatment options (NSAID + PPI; NSAID + H2-RA; NSAID + misoprostol; Arthrotec ® ), celecoxib will also result in a reduction in events in terms of total expected number of events and life-years lost. Table 7 also reports dominance (improved health at reduced cost) for the incremental cost-effectiveness ratios for celecoxib relative to the two alternative treatments, suggesting a highly favourable impact of introducing celecoxib in Norway for treatment of both OA and RA: significant cost reductions will be combined with increased health.
The model and its results were demonstrated to be relatively robust by using sensitivity analyses. Table 8 presents the results of the sensitivity analyses for the changes in the Fries risk scores, reduction in NSAID dosage in OA patients, reduction in ulcer and anaemia ratios, and changes in duration of therapy.
For OA, celecoxib demonstrates economic dominance in all sensitivity analyses against both base case and NSAID monotherapy, except for a reduction in NSAID dosage against monotherapy. This can be explained by an expected reduction in both drug costs and adverse events at lower NSAID dosages. However, the incremental cost/GI event averted (NOK 304 = US$35) and the incremental cost/life-year gained (NOK 5484 = US$630) are favourable, and still suggest that use of celecoxib will be of substantial benefit.
In the case of RA, celecoxib demonstrates economic dominance against the base case in all sensitivity analyses performed. Against NSAID monotherapy, however, celecoxib demonstrated dominance only for an increase in the Fries risk score (i.e. patients at higher risk of GI events), reduction in the ulcer/anaemia ratios, an increase in the duration of therapy and an increase in the costs of treating events. For other RA sensitivity analyses of celecoxib vs NSAID monotherapy, the model was susceptible to changes in the variables, with the leastfavourable incremental cost-effectiveness ratios observed for a decrease in the Fries risk score (i.e. patients at lower risk of GI events). This suggests that, as in the Swedish model [16] , the magnitude of the benefit of switching patients to celecoxib is dependent upon the absolute risk level of the patient population. However, the incremental costs calculated in this sensitivity analysis (NOK 849 = US$97/GI event averted and NOK 15 584 = US$1791/ life-year gained) are not unreasonable, and suggest that use of celecoxib even in patients with lower risk will have a favourable health and economic impact, especially considering that NSAID monotherapy is not necessarily the standard of care in clinical practice.
For the other variables that were susceptible to changes in probability (i.e. reduction in length of therapy and reduction in event costs), the favourable incremental costs suggest that use of celecoxib can still be costeffective under the specified conditions. Table 9 presents results of a sensitivity analysis that allows a post-event switch to celecoxib, in contrast to the basic analysis in which a post-event switch was only allowed to a treatment currently available on the Norwegian market (see Table 4 ). In this table, it can be seen that the magnitude of the cost-effectiveness for celecoxib compared with the other alternatives is reduced relative to the basic analysis (Table 5 ). There are two reasons for this reduction. The first is that, in the absence of the current availability of celecoxib, a post-event switch is made to a drug treatment that has a higher cost than celecoxib (e.g. NSAID + gastroprotective agent). The second is that, when celecoxib does become available, it will reduce the absolute risk of secondary events. Nevertheless, even with the reduced magnitude of the cost-effectiveness ratio, celecoxib still demonstrates Results are presented as expected cost differences per patient per year (NOK) between celecoxib and the treatment strategies with comparator agents. A negative sign indicates a reduction in cost with celecoxib, and dominance is demonstrated if improved health is obtained at reduced cost compared with the alternative. strong economic dominance compared with the alternative treatments. This suggests that the most cost-effective strategy for the management of OA and RA patients in Norway will be to use celecoxib as a first-line therapy.
Conclusions
The flexibility of the ACCES model is demonstrated in this analysis by its generalizability to the Norwegian clinical setting through the customization of variables specific for Norway. This model is significantly more advanced than other pharmacoeconomic models that have been developed for comparing costs of NSAIDs [18] [19] [20] [21] . It provides a wider range of comparators over a longer (and adjustable) duration of treatment, and greater flexibility in altering key variables to more accurately provide and predict real-world conditions. The use of data from observational databases in predicting the absolute risk of GI adverse events as well as NSAID relative risk rates also increases the validity of the model, since effectiveness rather than efficacy drives the model's outcome.
The practical results presented here using the ACCES model confirm that the favourable GI safety profile of celecoxib can be expected to result in improved health and substantial cost savings. The calculated 50-75% reduction in serious GI events combined with the reduction in ulcers and other GI events (anaemia, GI discomfort) can be expected to result in annual net savings with celecoxib, compared with initiating patients on NSAID monotherapy, of NOK 580 per OA patient and NOK 514 per RA patient. Compared with the base case, the estimated cost savings are even more significant. In a cost-effectiveness analysis, celecoxib demonstrated economic dominance (i.e. improved health at reduced cost) compared with the currently available alternatives. These results have been shown to be relatively robust by using sensitivity analyses to test the impact on results of key assumptions. While celecoxib consistently demonstrated economic dominance against the base case in all sensitivity analyses, the model was sensitive to several variables against NSAID monotherapy. However, even for the variable with the least favourable incremental cost-effectiveness ratio, use of celecoxib was still demonstrated to present a highly cost-effective alternative to NSAID monotherapy. Additionally, celecoxib provides cost savings compared with rofecoxib for the treatment of OA.
It can be concluded that the model predicts that the introduction of celecoxib into the Norwegian NSAID market, and its use as a first-line agent, will provide societal benefits in the form of improved health in patients with OA and RA. Reduced costs to the health care systems treating these patients are also predicted.
